$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

다발성경화증 치료를 위한 인터페론 베타의 산업적 생산
Industrial Production of Interferon Beta for the Treatment of Multiple Sclerosis 원문보기

KSBB Journal, v.33 no.2, 2018년, pp.70 - 75  

손다진 (강원대학교 생물공학과) ,  김종석 (강원대학교 생물공학과) ,  박재범 (강원대학교 생물공학과) ,  권덕호 (강원대학교 생물공학과) ,  정형무 (한국코러스제약) ,  한상인 (한국코러스제약) ,  홍억기 (강원대학교 생물공학과) ,  하석진 (강원대학교 생물공학과)

Abstract AI-Helper 아이콘AI-Helper

Multiple sclerosis is a chronic disorder commonly occurred in the central nervous system and is an autoimmune disease. Corticosteroids are used as a short-term treatment for multiple sclerosis, but they cause side effects. Therefore, interferon beta having antiviral and anti-inflammatory effects, is...

주제어

참고문헌 (42)

  1. Calabresi, P. A (2004) Diagnosis and management of multiple sclerosis. FP Essent. 70: 1935-1944. 

  2. Soldan, S. S., G. Wu, C. Markowitz, and D. L. Kolson (2008). Multiple sclerosis and other demyelinating diseases. pp. 239-255. In: H. E. Gendelman, T. Ikezu (eds.). Neuroimmune Pharmacol. Springer, Boston, MA. 

  3. Singh, V., S. Mehrotra, and S. Agarwal (1999) The paradigm of Th1 and Th2 cytokines. J Immunol Res. 20: 147-161. 

  4. Weinshenker, B. G (1996) Epidemiology of multiple sclerosis. Neurol Clin. 14: 291-308. 

  5. Cree, B. A. C (2014) Multiple sclerosis genetics. Handb Clin Neurol. 122: 193-209. 

  6. Dhib-Jalbut S. and S. Marks (2010) Interferon- ${\beta}$ mechanisms of action in multiple sclerosis. Neurology 74: S17-S24. 

  7. Kieseier, B. C (2011) The Mechanism of action of interferon- ${\beta}$ in relapsing multiple sclerosis. CNS Drugs 25: 491-502. 

  8. Goldenberg, M. M (2012) Multiple Sclerosis Review. Pharmacol. Ther. 37: 175-184. 

  9. Beck, R. W., P. A. Cleary, J. D. Trobe, D. I. Kaufman, M. J. Kupersmith, D. W. Paty, C. H. Brown, and O. N. S. Group (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N. Engl. J. Med. 329: 1764-1769. 

  10. La Mantia, L., M. Eoli, C. Milanese, A. Salmaggi, A. Dufour, and V. Torri (1994) Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur. Neurol. 34: 199-203. 

  11. Prisms, S (2001) PRISMS-4: Long-term efficacy of interferonbeta- 1a in relapsing MS. Neurology 56: 1628. 

  12. Paty, D., D. B. Li, U. M. M. S. Group, and I. M. S. S. Group (1993) Interferon beta?1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double?blind, placebo?controlled trial. Neurology 43: 662-662. 

  13. Simon, J. H., L. D. Jacobs, M. Campion, K. Simonian, N. Wende, D. L. Cookfair, R. A. Rudick, R. M. Herndon, J. R. Richert, and A. M. Salazar (1998) Magnetic resonance studies of intramuscular interferon ${\beta}$ -1a for relapsing multiple sclerosis. Ann Neurol. 43: 79-87. 

  14. Li, D. K., D. W. Paty, and UBC MS/MRI analysis research group (1999) Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon- ${\beta}$ 1 a in relapsing-remitting multiple sclerosis. Ann Neurol. 46: 197-206. 

  15. Rice, G., J. Oger, P. Duquette, G. S. Francis, M. Belanger, S. Laplante, and J. F. Grenier (1999) Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can. J. Neurol. Sci. 26: 276-282. 

  16. Sandig, V., T. Rose, K. Winkler, and R. Brecht (2005) Mammalian cells: Production of recombinant proteins: Novel microbial and eukaryotic expression systems, pp. 233-252. Wiley-VCH Weinheim, Germany, 

  17. Walsh, G (2014) Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32: 992-1000. 

  18. Aricescu, A. R. and R. J. Owens (2013) Expression of recombinant glycoproteins in mammalian cells: Towards an integrative approach to structural biology. Curr. Opin. Struct. Biol. 23: 345-356. 

  19. Zago, P., M. Baralle, Y. M. Ayala, N. Skoko, S. Zacchigna, E. Buratti, and S. Tisminetzky (2009) Improving human interferon- ${\beta}$ production in mammalian cell lines by insertion of an intronic sequence within its naturally uninterrupted gene. Biotechnol. Appl. Biochem. 52: 191-198. 

  20. Villela Dr. A., G. Renard, M. S. Palma, J. M. Chies, S. L. Dalmora, L. A. Basso, and D. S. Santos (2010) Human interferon Β1ser17: Coding DNA synthesis, expression, purification and characterization of bioactive recombinant protein. J. Microb. Biochem. Technol. 2: 1948-5948. 

  21. Mastrangeli, R., M. Rossi, M. Mascia, W. Palinsky, A. Datola, M. Terlizzese, and H. Bierau (2014) In vitro biological characterization of IFN- ${\beta}$ -1a major glycoforms. Glycobiology. 25: 21-29. 

  22. Han, Y. K., T. Y. Koo, and G. M. Lee (2009) Enhanced interferon- ${\beta}$ production by CHO cells through elevated osmolality and reduced culture temperature. Biotechnol. Prog. 25: 1440-1447. 

  23. Rodriguez, J., M. Spearman, N. Huzel, and M. Butler (2005) Enhanced Production of Monomeric Interferon- ${\beta}$ by CHO Cells through the Control of Culture Conditions. Biotechnol. Prog. 21: 22-30. 

  24. Spearman, M., J. Rodriguez, N. Huzel, K. Sunley, and M. Butler (2007) Effect of culture conditions on glycosylation of recombinant beta-interferon in CHO cells. pp. 71-85. In: Smith R. (eds) Cell Technology for Cell Products. Springer, Dordrecht, NL. 

  25. Spearman, M., J. Rodriguez, N. Huzel, and M. Butler (2005) Production and glycosylation of recobinant ${\beta}$ -interferon in suspension and cytopore microcarrier cultures of CHO cells. Biotechnol. Prog. 21: 31-39. 

  26. Song, K., I.S. Yoon, N. A. Kim, D. H. Kim, J. Lee, H. J. Lee, S. Lee, S. Choi , M. K. Choi, H. H. Kim, S. H. Jeong, and W. S. Son (2014) Glycoengineering of interferon- ${\beta}$ 1a improves its biophysical and pharmacokinetic properties. PloS ONE 9: e96967. 

  27. Mohan, C., Y. G. Kim, J. Koo, and G. M. Lee (2008) Assessment of cell engineering strategies for improved therapeutic protein production in CHO cells. Biotechnol. J. 3: 624-630. 

  28. Lai, T., Y. Yang, and S. K. Ng (2013) Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel) 6: 579-603. 

  29. Kamionka, M. (2011) Engineering of therapeutic proteins production in Escherichia coli. Curr. Pharm. Biotechnol. 12: 268-274. 

  30. Rao, D. V. K., C. T. Ramu, J. V. Rao, M. L. Narasu, and A. K. S. B. Rao (2009) Cloning, high expression and purification of recombinant human Intereferon- ${\beta}$ -1b in Escherichia coli. Appl. Biochem. Biotechnol. 158: 140-154. 

  31. Harde, D. R., M. Knauf, and E. Croze (1995) The use of zwittergent 3-14 in the purification of recombinant human interferon- ${\beta}$ ser17 (Betaseron). J. Interferon Cytokine Res. 15: 31-37. 

  32. Ashnagar, F., M. Khodabandeh, A. Arpanaei, Z. A. Sadigh, F. Rahimi, and P. Shariati (2014) Optimizing primary recovery and refolding of human interferon-b from Escherichia coli inclusion bodies. Iran J. Biotechnol. 12: 26-34. 

  33. Sahdev, S., S. K. Khattar, and K. S. Saini (2008) Production of active eukaryotic proteins through bacterial expression systems: A review of the existing biotechnology strategies. Mol. Cell Biochem. 307: 249-264. 

  34. Skoko, N., B. Argamante, N. K. Grujicic, S. G. Tisminetzky, V. Glisin, and G. Ljubijankic (2003) Expression and characterization of human interferon- ${\beta}1$ in the methylotrophic yeast Pichia pastoris. Biotechnol. App.l Biochem. 38: 257-265. 

  35. Goffeau, A., B. G. Barrell, H. Bussey, R. W. Davis, B. Dujon, H. Feldmann, F. Galibert, J. D. Hoheisel, C. Jacq, M. Johnston, E. J. Louis, H. W. Mewes, Y. Murakami, P. Philippsen, H. Tettelin, and S. G. Oliver (1996) Life with 6000 genes. Science 274: 546-567. 

  36. Feizi, A., T. Osterlund, D. Petranovic, S. Bordel, and J. Nielsen (2013) Genome-scale modeling of the protein secretory machinery in yeast. PloS ONE 8: e63284. 

  37. Mattanovich, D., B. Gasser, H. Hohenblum, and M. Sauer (2004) Stress in recombinant protein producing yeasts. J. Biotechnol. 113: 121-135. 

  38. Mattanovich, D., P. Branduardi, L. Dato, B. Gasser, M. Sauer, and D. Porro (2012) Recombinant protein production in yeasts. pp. 329-358. In: Lorence A. (eds) Recombinant Gene Expression. Methods in Molecular Biology (Methods and Protocols). Humana Press, Totowa, NJ. 

  39. Arnold, S. and C. Scheckermann (2012) Method for the purification of interferon-B. US Patent, 424/85.6; 530/351. 

  40. Chernajovsky, Y., Y. Mory, L. Chen, Z. Marks, D. Novick, M. Rubinstein, and M. Revel (1984) Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN- ${\beta}1$ gene fused to an SV40 early promoter. DNA3: 297-308. 

  41. McCormick, F. R. A. N. K., M. Trahey, M. I. C. H. A. E. L. Innis, B. Dieckmann, and G. Ringold (1984) Inducible expression of amplified human beta interferon genes in CHO cells. Mol. Cell. Biol. 4: 166-172. 

  42. Romanov, V. P., V. V. Bezuglov, M. Y. Bobrov, T. I. Kostromina, S. A. Feofanov, and A. I. Miroshnikov (2011) Isolation of human interferon ${\beta}1b$ (Ser17) expressed in E. coli with the use of ion-exchange chromatography. Russ. J. Bioorganic. Chem. 37: 292-297. 

저자의 다른 논문 :

관련 콘텐츠

오픈액세스(OA) 유형

BRONZE

출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로